---
title: "eDiagnosis's Kunjin virus nucleic acid detection kit approved for market launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282823614.md"
description: "According to eDiagnosis, the nucleic acid detection kit for Chikungunya virus has officially been approved for market launch. This kit is the first approved premixed nucleic acid detection kit for Chikungunya virus in China, featuring high sensitivity and high specificity detection performance, providing solid technical support for the early detection, early reporting, and early diagnosis and treatment of Chikungunya fever"
datetime: "2026-04-15T10:15:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282823614.md)
  - [en](https://longbridge.com/en/news/282823614.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282823614.md)
---

# eDiagnosis's Kunjin virus nucleic acid detection kit approved for market launch

According to eDiagnosis, the nucleic acid test kit for Chikungunya virus has officially been approved for market launch. This kit is the first approved premixed nucleic acid test kit for Chikungunya virus in China, featuring high sensitivity and high specificity detection performance, providing solid technical support for the early detection, early reporting, and early diagnosis and treatment of Chikungunya fever

### Related Stocks

- [002932.CN](https://longbridge.com/en/quote/002932.CN.md)

## Related News & Research

- [10:30 ETEpigenetics Market worth $3.92 billion by 2031 | MarketsandMarkets™](https://longbridge.com/en/news/290980619.md)
- [06:03 ETSperidian Technologies Launches FinOps for AI Offering to Help Enterprises Turn AI Investment into Measurable Efficiency and Growth](https://longbridge.com/en/news/290811426.md)
- [Mercedes VLE first drive: Luxury electric travel with 800-volt technology and open windows](https://longbridge.com/en/news/290857853.md)
- [09:47 ETADAMA Announces Launch of Novali™, a High-Load Liquid Pyroxasulfone Herbicide for Row Crops](https://longbridge.com/en/news/290704210.md)
- [Coiled Therapeutics: AO-252 delivers promising clinical results and commercial potential as the only clinical-stage TACC3 inhibitor](https://longbridge.com/en/news/290784764.md)